ImmuneOncia: A PD-L1 Latecomer Hoping To Break Into The Market

 
• By Jung Won Shin

Emerging Company Profile: ImmuneOncia may be late entering the market for PD-L1 inhibitors, but the joint venture between Yuhan and Sorrento Therapeutics aims to develop best-in-class immuno-oncology drugs with differentiated products and strategy.

Emerging Company Profile Regular column feature image Version 2

More from Start-Ups & SMEs

More from Business